Novartis Skin Drug Helps Patients With Chronic Hives Reviewed by Momizat on . Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study. The seco Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study. The seco Rating: 0
You Are Here: Home » Health » Novartis Skin Drug Helps Patients With Chronic Hives

Novartis Skin Drug Helps Patients With Chronic Hives

Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study.

The second of three late-stage studies found that more than one third of patients with chronic spontaneous urticaria (CSU) who were treated with the drug were completely itch and hive-free after 12 weeks compared to 5 percent of patients on placebo.

Omalizumab, which is also known as Xolair, is already approved for treating severe asthma. Novartis said it was on track to submit omalizumab for regulatory approval in patients with CSU later this year.

About The Author

Number of Entries : 18593
Contact us  |  +23412131214

© 2013 Channels Incorporated Limited - Powered by IDS Africa Limited

Scroll to top